{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-171240","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.695551+00:00","generated_at":"2026-06-13T20:12:25.116077+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Lyell Immunopharma shareholders elect 3 directors, ratify EY, approve say-on-pay annually","bullets":["Three Class II directors elected: Klausner (150.6M for), Brawley (143.1M for), Rieflin (150.0M for).","Ernst & Young LLP ratified as auditor for FY 2023 with 187.8M votes for, 16.9K against.","Say-on-pay approved with 131.5M votes for, 3.3M against, 19.2M abstentions; broker non-votes 33.9M.","Advisory vote on frequency: 143.0M preferred every 1 year; Board adopted annual say-on-pay policy.","Say-on-pay frequency policy in effect until next required vote no later than 2029 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-171240","json":"https://secwatch.observer/filing/0001193125-23-171240.json","markdown":"https://secwatch.observer/filing/0001193125-23-171240.md","text":"https://secwatch.observer/filing/0001193125-23-171240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/d695920d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:12:25.116077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42b352166a8d8aca9052bf6823c8cbeba43f8559","claim":"Lyell Immunopharma, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-16 meeting.","evidence_excerpt":"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 187,794,458 16,913 39,312 187,850,683","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"830248f32720e6d08e41465fc93120f64ff0c051","claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2023-06-16 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 131,476,834 3,278,721 19,180,844 33,914,284 187,850,683","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"cc5eae02ac84131eccfc172ba243048a86503953","claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote on preferred frequency of stockholder advisory votes on executive compensation at the 2023-06-16 meeting.","evidence_excerpt":"To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes to approve the compensation of the Company’s named executive officers. The voting results were as follows: Vote For Every One Year Vote For Every Two Years Vote For Every Three Years Abstentions Broker Non-Votes Total 142,962,684 695 33,332 10,939,688 33,914,284 187,850,683","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"d4fae927ced9b1f888c964a512c73c32686f33a2","claim":"Lyell Immunopharma, Inc. shareholders approved Election of three Class II directors at the 2023-06-16 meeting.","evidence_excerpt":"To elect the following three Class II directors to hold office until the Company’s 2026 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 150,646,318 3,290,081 33,914,284 187,850,683 Otis Brawley, M.D. 143,059,192 10,877,207 33,914,284 187,850,683 William Rieflin 150,032,005 3,904,394 33,914,284 187,850,683","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}